Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Operating Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Operating Expenses for 6 consecutive years, with $16.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 12.41% to $16.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.7 million through Dec 2025, down 4.86% year-over-year, with the annual reading at $78.7 million for FY2025, 4.86% down from the prior year.
  • Operating Expenses for Q4 2025 was $16.9 million at Maxcyte, down from $19.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $22.2 million in Q1 2024, with the low at $10.7 million in Q2 2021.
  • Average Operating Expenses over 5 years is $18.1 million, with a median of $19.3 million recorded in 2024.
  • The sharpest move saw Operating Expenses surged 60.38% in 2022, then dropped 12.96% in 2024.
  • Over 5 years, Operating Expenses stood at $13.9 million in 2021, then grew by 26.99% to $17.6 million in 2022, then grew by 25.87% to $22.2 million in 2023, then decreased by 12.96% to $19.3 million in 2024, then fell by 12.41% to $16.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $16.9 million, $19.4 million, and $21.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.